micro dose of glp 1 GLP-1 microdosing is popular, but there's little evidence it works Thinking About Microdosing GLP-1? 5

Structural basis for the interaction of antibiotics with the peptidyl transferase centre in eubacteria

Capture, crawl, cross: the T cell code to breach the blood-brain barriers

It eliminates the need for ongoing medication management and the risk of serious adverse events associated with GLP-1 drugs, such as pancreatitis and thyroid issues

In the United States, Medicare coverage for L-carnitine is available for patients who have been on dialysis therapy for at least 3 months, have a plasma free carnitine level less than 40 mol/L, and have erythropoietin-resistant anemiathat has not responded to standard erythropoietin dosageand for which other causes have been investigated and adequately treated. 195 Hyporesponsiveness to ESAs is not specifically defined other than having a persistent Hct less than 30% despite erythropoietin dosage that is considered clinically appropriate to treat the particular patient. The statement There is insufficient evidence to recommend use of L-carnitine in the management of anemia in patients with CKD is supported by results from 6 available RCTs of IV L-carnitine administration to ESA-treated HD patients (Table 32)

Shake gently before use